A Hit and a Miss for Novel Autism Drug

The novel treatment balovaptan is not statistically superior to placebo for improved social communication in autism spectrum disorder, results from a large phase 2 trial show.

Related Keywords

New York ,United States ,Eric Hollander ,Rachel Brown ,Roche Ltd ,Albert Einstein College Of Medicine ,Drug Administration ,University Of Kansas School Medicine ,Obsessive Compulsive Spectrum Program ,Us Department Of Defense ,Behavioral Sciences ,Elsevier ,Albert Einstein College ,Medscape Medical ,Medscape Medical News ,Vineland Adaptive Behavior ,Kansas School ,Autism Spectrum Disorder ,Autism ,Behavior Problems ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Atrial Septal Defects ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Congenital Heart Disease ,Vasopressin ,Antidiuretic Hormone ,Dh Antidiuretic Hormone ,Activism ,Activist ,Adolescent M ,